Cost effectiveness of screen-and-treat strategies for low bone mineral density: How do we screen, who do we screen and who do we treat?

Applied Health Economics and Health Policy

Volumn 6, Issue 1, 2008, Pages 1-18

  Schousboe, John T ^a,b  

^a PARK NICOLLET CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bone mineral density; Cost effectiveness; Screening

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ETIDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; RALOXIFENE; ZOLEDRONIC ACID;

BONE DENSITOMETRY; BONE DENSITY; COST EFFECTIVENESS ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HIGH RISK PATIENT; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; SCREENING;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY-ADJUSTED LIFE YEARS;

EID: 51849099994     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200806010-00001     Document Type: Review

References (85)

1. Nguyen ND, Ahlborg HG, Center JR, et al. Residual lifetime risk of fractures in women and men. J Bone Miner Res 2007 Jun; 22 (6): 781-8
2. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007 Mar; 22 (3): 465-75
3. Leslie WD, Macwilliam L, Lix L, et al. A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service. Osteoporos Int 2005 Jul; 16 (7): 773-82
4. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J 2007 Aug; 83 (982): 509-17
5. ACOG Committee on Practice. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists. Osteoporosis Number 50, January 2003. Obstet Gynecol 2004 Jan; 103 (1): 203-16
6. National Osteoporosis Foundation. Physician guide to prevention and treatment of osteoporosis [online]. Available from URL: http://www.nof.org/ professionals/Clinicians_Guide.htm [Accessed 2005 Jan 15]
7. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Revised 2004 Aug 26. CMAJ 2004 Nov 12; 167 (10 Suppl.): S1-34
8. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003 Nov-Dec; 9 (6): 544-64
9. Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997; 7 (4): 390-406
10. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001 Feb 1; 344 (5): 333-40
11. McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007 Jan; 22 (1): 135-41
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288 (3): 321-33
13. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996 Dec 7; 348 (9041): 1535-41
14. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 May 3; 356 (18): 1809-22
15. Chesnut 3rd CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000 Sep; 109 (4): 267-76
16. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999 Aug 18; 282 (7): 637-45
17. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998 Dec 23-30; 280 (24): 2077-82
18. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999 Oct 13; 282 (14): 1344-52
19. Delmas PD, Recker RR, Chesnut 3rd CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004 Oct; 15 (10): 792-8
20. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 May 10; 344 (19): 1434-41
21. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11 (1): 83-91
22. Dawson-Hughes B, Lindsay R, Khosla S, et al. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008 [online]. Available from URL: http://www.nof.org/professionals/ NOF_Clinicians_Guide.pdf [Accessed 2008 May 11]
23. Centers for Medicare and Medicare Services. Physician fee schedule search 2007 [online]. Available from URL: http://www.cms.hhs.gov/pfslookup/ 02_pfssearch.asp [Accessed 2007 Mar 4]
24. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004 Jun; 19 (6): 893-9
25. Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 2007; 25 (11): 913-33
26. Zethraeus N, Borgstrom F, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis: a review of the literature and a reference model. Osteoporos Int 2007 Jan; 18 (1): 9-23
27. Zethraeus N, Ben Sedrine W, Caulin F, et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporosis Int 2002; 13 (11): 841-57
28. Eddy DM, Johnston Jr CC, Cummings SR, et al. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998; 8 Suppl. 4: S3-S88
29. Schousboe JT. Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures. Curr Rheumatol Rep 2007; 9 (1): 50-6
30. Tosteson AN, Jonsson B, Grima DT, et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporosis Int 2001; 12 (10): 849-57
31. Dawson-Hughes B, Tosteson AN, Melton 3rd LJ, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008 Apr; 19 (4): 449-58
32. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008 Apr; 19 (4): 385-97
33. Borgstrom F, Johnell O, Kanis JA, et al. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 2006 Oct; 17 (10): 1459-71
34. Tosteson AN, Melton 3rd LJ, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008 Apr; 19 (4): 437-47
35. Garton MJ, Cooper C, Reid D. Perimenopausal bone density screening: will it help prevent osteoporosis? Maturitas 1997 Jan; 26 (1): 35-43
36. Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 1996; 6 (4): 265-75
37. Tosteson AN, Rosenthal DI, Melton 3rd LJ, et al. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990 Oct 15; 113 (8): 594-603
38. Brown MA, Bradlow J, Gray AM. Cost effectiveness of bone density measurements. J Br Menopause Soc 2001; 7 (3): 130-5
39. Mobley LR, Hoerger TJ, Wittenborn JS, et al. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making 2006 Mar-Apr; 26 (2): 194-206
40. Schousboe JT, Ensrud KE, Nyman JA, et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005 Oct; 53 (10): 1697-704
41. Pfister AK, Welch CA, Lester MD, et al. Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 2006 Feb; 99 (2): 123-31
42. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007Aug 8; 298 (6): 629-37
43. Schwenkglenks M, Lippuner K. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int 2007 Nov; 18 (11): 1481-91
44. Solomon DH, Kuntz KM. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. Arthritis Rheum 2000 Sep; 43 (9): 1967-75
45. Borgstrom F, Jonsson B, Strom O, et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 2006 Dec; 17 (12): 1781-93
46. Sugarman JR, Connell FA, Hansen A, et al. Hip fracture incidence in nursing home residents and community-dwelling older people, Washington State, 1993-1995. J Am Geriatr Soc 2002 Oct; 50 (10): 1638-43
47. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006 Jul 13 2006; 355 (2): 125-37
48. Borgstrom F, Johnell O, Kanis JA, et al. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004; 22 (17): 1153-65
49. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005 Mar; 16 Suppl. 2: S3-7
50. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004 Jul 1; 117 (1): 19-25
51. Meadows ES, Klein R, Rousculp MD, et al. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health 2007; 7: 6
52. Ben Sedrine W, Broers P, Devogelaer JP, et al. Interest of a prescreening questionnaire to reduce the cost of bone densitometry. Osteoporos Int 2002 May; 13 (5): 434-42
53. Schott AM, Ganne C, Hans D, et al. Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int 2007 Feb; 18 (2): 143-51
54. Richy F, Ethgen O, Bruyere O, et al. Primary prevention of osteoporosis: mass screening scenario or prescreening with questionnaires? An economic perspective. J Bone Miner Res 2004 Dec; 19 (12): 1955-60
55. Cadarette SM, McIsaac WJ, Hawker GA, et al. The validity of decision rules for selecting women with primary osteoporosis for bone mineral density testing. Osteoporos Int 2004 May; 15 (5): 361-6
56. Gourlay ML, Miller WC, Richy F, et al. Performance of osteoporosis risk assessment tools in postmenopausal women aged 45-64 years. Osteoporos Int 2005 Aug; 16 (8): 921-7
57. Geusens P, Hochberg MC, van der Voort DJ, et al. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc 2002 Jul; 77 (7): 629-37
58. Adler RA, Tran MT, Petkov VI. Performance of the Osteoporosis Self-assessment Screening Tool for osteoporosis in American men. Mayo Clin Proc 2003 Jun; 78 (6): 723-7
59. Langton CM, Ballard PA, Langton DK, et al. Maximising the cost effectiveness of BMD referral for DXA using ultrasound as a selective population pre-screen. Technol Health Care 1997 Jul; 5 (3): 235-41
60. Kraemer DF, Nelson HD, Bauer DC, et al. Economic comparison of diagnostic approaches for evaluating osteoporosis in older women. Osteoporos Int 2006 Jan; 17 (1): 68-76
61. Sim MF, Stone MD, Phillips CJ, et al. Cost effectiveness analysis of using quantitative ultrasound as a selective prescreen for bone densitometry. Technol Health Care 2005; 13 (2): 75-85
62. Marin F, Lopez-Bastida J, Diez-Perez A, et al. Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in postmenopausal women from the general population: a cost-effectiveness analysis. Calcif Tissue Int 2004 Mar; 74 (3): 277-83
63. Sim MF, Stone M, Johansen A, et al. Cost effectiveness analysis of BMD referral for DXA using ultrasound as a selective pre-screen in a group of women with low trauma Colles' fractures. Technol Health Care 2000; 8 (5): 277-84
64. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005 Nov; 16 (11): 1330-8
65. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005 Feb 2005; 16 (2): 155-62
66. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005 Jul; 16 (7): 737-42
67. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004 Aug; 35 (2): 375-82
68. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005 Jul; 20 (7): 1185-94
69. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007 Aug; 18 (8): 1033-46
70. Schousboe JT, Ensrud KE, Nyman JA, et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for aminobisphosphonate therapy. Osteoporos Int 2005 Dec; 16 (12): 1883-93
71. Schousboe JT, Ensrud KE, Nyman JA, et al. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score >-2.5 for alendronate therapy: a modeling study. J Clin Densitom 2006 Apr-Jun; 9 (2): 133-43
72. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008 Apr; 19 (4): 399-428
73. McCloskey E, Johansson H, Oden A, et al. Comparison of European and WHO strategies for the identification of women at risk of hip fracture [abstract]. Osteoporos Int 2007; 18 (1): S23
74. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998; 8 (5): 468-89
75. Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007; 30 (9): 755-63
76. Herndon MB, Schwartz LM, Woloshin S, et al. Implications of expanding disease definitions: the case of osteoporosis. Health Aff (Millwood) 2007 Nov-Dec; 26 (6): 1702-11
77. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007 May 3; 356 (18): 1895-6
78. Pickney CS, Arnason JA. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 2005 Sep; 16 (9): 1156-60
79. Pressman A, Forsyth B, Ettinger B, et al. Initiation of osteoporosis treatment after bone mineral density testing. Osteoporos Int 2001; 12 (5): 337-42
80. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005 Nov 14; 165 (20): 2414-9
81. Silverman SL, Greenwald M, Klein RA, et al. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol 1997 Mar; 89 (3): 321-5
82. Sedlak CA, Doheny MO, Estok PJ, et al. DXA, health beliefs, and osteoporosis prevention behaviors. J Aging Health 2007 Oct; 19 (5): 742-56
83. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002 Mar; 112 (4): 281-9
84. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004 Fall; 7 (3): 255-61
85. Borgstrom F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006; 17 (5): 637-50